V502

**V502** was Merck's investigational prophylactic octavalent human papillomavirus vaccine. It contained recombinant L1 major-capsid-protein virus-like particles from HPV types 6, 11, 16, 18, 31, 45, 52, and 58, formulated with amorphous aluminum hydroxysulfate and ISCOMATRIX. The noninfectious VLP antigens were designed to induce type-specific neutralizing antibody responses that prevent new HPV infections and associated genital warts, cervical cancer, vulvar cancer, vaginal cancer, and related precancerous lesions. Merck evaluated V502 in Phase 1 and Phase 2 clinical studies, but the Phase 2 efficacy study was withdrawn and the program did not become a marketed vaccine. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00851643))

Other names

human papillomavirus vaccine recombinant octavalentoctavalent human papillomavirus L1 virus-like particle vaccineoctavalent human papillomavirus virus-like particle vaccine